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Chapter I.: Early detection of testicular cancer 
1. Introduction 
Primary testicular cancers (TC) are the most common solid malignant tumors 
in men between the ages of 20 and 35 years. Due to its highly sensitive to 
chemotherapy, germ cell testicular cancer (GCTC) have become an excellent 
testing ground for active experimental drugs. TC has been a model for 
multidisciplinary care, as close cooperation between professional areas do improve 
the cure rate. TCs are highly curable: cure rates for good-risk disease are 90-95%, 
and significant even in patients with metastatic disease at diagnosis. The prognosis 
depends upon the histologic type of cancer (seminoma (S) versus nonseminoma 
(NS)), stage, and other features such as tumor marker and localization of distant 
metastasis. 
As stage is one of the most significant determinants of survival, the earlier we 
can detect TC, the greater chance we could achieve longer survival. Early 
detection of TC theoretically can be improved by spreading medical information 
on the importance of self-examination and the curability of TC, and on multimodal 
treatment possibilities. Testicular self-examination (TSE) is an important activity 
that men should be taught to detect any early changes that may be signs of 
pathological significance. Poor public awareness of the disease and lack of TSE 
may account for late presentation. According to statistics, the delay from initial 
symptoms to definitive diagnosis by radical orchiectomy has averaged 4 to 5 
months. 
The most common presenting symptom is painless enlargement or swelling, 
firmness, or nodule/lump of one testicle (asymmetry), that cannot be separated 
from the testis. In most cases the hard irregular mass filling a part or the whole 
testis. Disseminated disease have symptom of lymphatic or hematogenous spread. 
During differential diagnosis one should consider epididymitis, hematoma, 
orchitis, varico- and hydrocele, inguinal hernia, testicular torsion, spermatocele, 
syphilitic gumma and probably iliac or caval venous obstruction or thrombosis. 
Testicular palpation and US examination of the testis (TUS) usually confirms 
the diagnosis, and helps distinguish between TC and other intrascrotal pathologies. 
The tumor tissue type cannot be reliably differentiated solely by its 
ultrasonographic appearance, but certain characteristics could draw the attention 
on seminomas (S) or nonseminomas (NS). Although the specificity and sensitivity 
have not been reported, general consensus exists that a palpable mass with an US 
finding of a solid or mixed cystic and solid hypoechoic intratesticular mass is an 
indication for surgical exploration and radical inguinal orchiectomy.  
Radical inguinal orchiectomy is the definitive procedure to provide local 
tumor control and to permit histological evaluation of the primary tumor. 
Retroperitoneal lymph node dissection (RPLND) is the standard and reliable 
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method to identify nodal micrometastases and provide accurate pathologic staging 
of the retroperitoneal spread. Both the number and size of involved retroperitoneal 
lymph nodes are of prognostic importance. Moreover, the availability of reliable 
tumor markers (AFP, ß-hCG, LDH) has greatly facilitated the management of 
GCTC. An extended diagnostic work-up require to rule out metastatic disease. The 
standard staging examinations are radiological imaging (CT scan, MRI, in case of 
suspicion bone scan, and PET/CT). 
Various staging systems have been used to classify and subsequently manage 
patients with TC. Staging based on the TNM and the AJCC staging system, that 
were integrated with risk classification as well by the IGCCCG classification 
system. The following prognostic factors are considered: the site of primary tumor 
(testicular or extragenital), histological type of tumor (S or NS), localization of 
metastases (visceral or nonvisceral) and the levels of serum tumor markers.  
The prognosis of men with TC has improved markedly following the 
introduction of cisplatin-based chemotherapy. It has also been demonstrated that 
treatment in specialized centers results in a better clinical outcome. The main goal 
of the rationalized the risk-adapted treatment policy is to select and treat patients 
according to their individual clinical risk, decrease side effects and treatment costs, 
and increase the patient’s quality of life. Initial therapy is selected according to 
AJCC stage group; risk stratification (good, intermediate, or poor risk), as per the 
guidelines of IGCCCG and histology (S versus NS). 
2. Aim of the Thesis  
For the above-mentioned statements we started an educational and screening 
program in order to determine: 
1. the efficacy of this early detection program on by the analysis of the 
figures of TC found; 
2. results after the changes in delay in the diagnosis of TC; 
3. changes in mortality in TC. 
3. Patients and methods  
A media and teach-in campaign organized by National Cancer League on the 
early signs and the risk factors of TC, the correct method of testicular self 
examination (TSE) and the importance of early detection were conducted. 
Volunteers who demanded testicular screening were invited to an appointment for 
medical examination. Recruitment was not limited to any age groups or complaint 
categories, as we intended to analyze the demographic characteristics and the 
presence or absence of complaints of the volunteers. The medical examination 
consisted of  
- physical and  
- US examination of the testicles and  
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- in any case of suspicious malignancy tumor markers (AFP, ß-hCG) were also 
checked. 
An Acuson 128 PX US device, with a 7 MHz linear transducer was used for 
the testicular ultrasound examination (TUS). A single type of non-malignant 
pathological finding was considered as one pathological event regardless of 
bilateral or multiple appearances: for example testicular cysts, hydroceles, etc. 
Between April 1995 and April 1998 5056 volunteers participated in the program.  
Findings were analyzed according to the volunteers classification, who were 
divided into two main groups based on a./ the presence or b./ absence of 
complaints. Volunteers with complaints were subdivided according to the nature of 
the complaint observed through TSE: a./pain; b./sensitivity to palpation of the 
testicle; c./palpable lump; d./ swelling of the testicle, or e./ a complaint unrelated 
to the testicle, such as dysuria, impotence etc. If multiple complaints were present, 
we classified them according to their most important one. When TC was detected 
clinical details are also presented. Clinical staging, histological classification of the 
tumors, course of treatment, way of response evaluation and follow-up of patients 
was in line with the institutional policy at that time. Delay in the diagnosis of 
patients treated by chemotherapy in our Department in 1994 and in 1998 was also 
retrospectively analyzed and compared to measure the educational impact of the 
program. Mortality rate of TC patients in Hungary between 1994 and 1998, and 
subsequent years was also analyzed in order to detect the probable impact of our 
early detection program on survival. 
The proportions of the findings between the complaints free and the with-
complaints population were compared using the Chi-square test. The diagnostic 
and medical delays between 1994 and 1998 were analyzed by the Student-t test. A 
difference was regarded as significant if the P value was < 0.05. 
4. Results 
The median age of the 5056 volunteers was 42 years (range 16-76 years), and 
32 tumors were diagnosed in 30 patients (0.6%).  
Among the 5056 volunteers, 2714 were complaint-free and 2342 patients 
presented different complaints. In the complaint-free population 1323 men had no 
physical or radiology findings (49%), but in the remaining 1391 men 1599 
different findings were detected by physical examination and/or TUS. No tumors 
were found in the complaint-free population. Of the 2342 men with different 
complaints, 532 (23%) had no detectable findings, but in the remaining 1810 men 
2194 findings were discovered. The incidence of patients with tumors in this 
subgroup (i. e. both complaints and findings) was 1.66% (30/1810) representing 
1.37% (30/2194) of the findings detected. The incidence of men having tumor in 
the group of 2342 volunteers with complaints was 1.28% (30/2342). Although, the 
frequency of findings in the complaint-fee and the with-complaints population 
were nearly equal (1.15 and 1.21 findings/man, respectively), a highly significant 
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relationship can be detected between complaints and findings: χ2=366,7 
(p<<0,0001) 
The abnormal findings in the group of volunteers with complaints were 
significantly more often than in the complaint-free population (77% vs 
51%,respectively; p<0.001). Cysts (p<0.001), hydroceles (p<0.001) and 
epididymitis (p<0.001) occurred more frequently in the group with complaints. 
Patients with clinically detected significant nonmalignant abnormalities were 
referred to an urologist (3.9% in the with-complaint vs 0.9% and complaint-free 
group). The remaining were informed about their findings and were directed to a 
general practitioner, with suggestions for treatment. A history of cryptorchidism 
was noted in 1.9% of the men with complaints and in 0.8% of the complaint-free 
population (p<0.001). 
The volunteers with complaints were subdivided according to their main 
symptoms as follows: 457 (20,8%) had testicular pain, 782 (35,6%) had sensitivity 
to palpation of the testicle, 477 patients (21,7%) had palpable lump, 249 (11,3%) 
had swollen testicle, and 229 patients (10,4%) had symptoms unrelated to the 
testicles. We did not find any tumor in the group with pain, sensitivity, or 
complaints unrelated to the testicle; these abnormalities were mainly of cysts, 
hydroceles and varicoceles.  
Of the 464 men who palpated a lump, 64 (14%) had no detectable 
abnormalities. Together 477 lumps were discovered, among them 22 tumors. The 
incidence of tumors in the group of men with palpated lump was 4.74% (22/464), 
and these represented 4,61% (22/477) of all lumps. However, in case of palpable 
lump cysts and varicoceles and hydroceles were the most frequent findings. 
Table 1. Distribution of findings in the complaint-free population and in the population 
with complaints 
Findings Complaint-
free 
population 
Population 
with 
complaints 
P Complaint- 
free 
population 
Population 
with 
complaints 
 2714 
volunteers 
2342 
volunteers 
 1599 findings 2194 findings 
 N % N %  % % 
Epididymal 
and testicular cyst 
526 19.4 676 28.9 <0.001 32.9 30.8 
Testicular atrophy 124 4.6 136 5.8 0.06 7.8 6.2 
Hydrocele 480 17.7 585 25.0 <0.001 30.0 26.7 
Epididymitis 39 1.4 232 9.9 <0.001 2.4 10.6 
Varicocele 399 14.7 497 21.2 0.10 25.0 22.7 
Tumor 0 0.0 30* 1.3 <0.001 0.0 1.5 
Microcalcification 11 0.4 11 0.5 0.73 0.7 0.5 
Others 20 0.7 25 1.1 0.22 1.3 1.1 
*30 patients with 32 tumors 
Among the 228 men whose main complaint was swollen testicle, no 
abnormalities were detected in 13 (5.4%), but in the remaining 215 men had 249 
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findings, with 10 tumors in between. The incidence of patients with tumor was 
4.38% (10/228) in this group, representing 4.01% (10/249) of all detected 
swollenness. Hydrocele was the most frequent finding in men (56%) with a 
swollen testicle.  
Table 2. Findings according to the volunteers’ main complaint 
Findings Pain Sensitivity Palpable lump Swollen 
testicle 
Unrelated 
complaints 
all N of findings 457 782 477 249 229 
 N % N % N % N % N % 
Epididymal and 
testicular cyst 
125 27,4 246 31,5 207 43,4 46 18,5 52 22,7 
Testicular 
atrophy 
20 4,4 63 8,1 11 2,3 10 4,0 32 14,0 
Hydrocele 103 22,5 209 26,7 75 15,7 139 55,9 59 25,8 
Epididymitis 62 13,6 88 11,2 50 10,5 19 7,6 13 5,7 
Varicocele 141 30,9 169 21,6 98 20,6 21 8,4 68 29,7 
Tumor 0 0 0 0 22 4,6 10 4,0 0 0 
Microcalcification  2 0,4 4 0,5 2 0,4 0 0,0 3 1,3 
Other 4 0,8 3 0,4 12 2,5 4 1,6 2 0,8 
All men 373 636 464 228 186 
During the 3-year period, 4 benign testicular tumors were discovered among 
5056 volunteers (0.08%). The histological findings were: cavernous hemangioma, 
dermoid cyst, Leydig-cell tumor and adenomatoid tumor. Testicular exploration 
helped to identify benign lesions, and allowed testicular preservation in two cases. 
Out of the 26 men with TC, two patients with bilateral synchronous Ss were 
detected. The frequency of detection of bilateral GCTC during the screening 
program (7%) is probably a statistical artifact, since the incidence of bilateral 
synchronous TC is about only 0.5%. Among the 26 men with GCTC, 19 stage I. 
tumors were detected. The median age was 33 years (range of 20-48 years) and the 
overall median duration of complaints was less than 12 weeks (range 1-48 weeks). 
Fifteen S (2 of them bilateral), and 13 NS tumors were diagnosed. The clinical 
stages were: 9 I/A, 9 I/B, 1 I/S, 3 II/A, 1 II/B, and 2 III/B. One patient refused any 
further treatment and was lost of follow-up.  
Because of the early stages and the high percentage of S, the tumor markers 
aided in cancer diagnosis in only 8 cases: 7 with increased β-hCG and 4 with 
increased AFP were detected. Both β-hCG and AFP were elevated in 3 cases. 
Elevated tumor markers in all except on were NSs. 
The occurrence of TC was most frequent (1.6%) in the 15 to 40 age group. 
Only 3 TC were detected in men over the age of 45 (0.3 %), two of these revealed 
S. According to the IGCCCG classification, all patients belonged to the good 
prognostic group, except for the patient who was lost to follow-up after 
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orchidectomy. The median follow up time of patients in December 1999 was 36 
months (16-49 months). At this time all patients were cured. 
Concerning the educational aspect of the program, we did not observe a 
significant decrease in the diagnostic and medical delay in the patient population 
treated by chemotherapy in our department between 1994 and 1998 (p=0.58). 
There is a non-significant tendency for a decrease in the duration of medical delay 
in favor of 1998 especially in stage III patients, suggesting a greater awareness of 
the need for treatment, especially among stage III patients.  
The data shows that there were a clear decrease between 1985-1994, there 
were no significant changes in the figures of death rates in this following years. 
However there were a period between 1997 and 2002, where the number of deaths 
were clearly and continuously under the regression curve, that is followed by a 
discrete elevation in the recent years. 
5. Discussion 
The results of the early detection program confirm that the screening of 
asymptomatic patients does not necessarily lead to the detection of tumors, and the 
incidence of detected tumors is low even in volunteers with complaints. The 
results show that the probability of detecting existing pathology is much higher in 
the population with complaints than in volunteers without complaints. However, 
diagnosed pathology which required further urological health care still remained 
low. 
No tumors were found in the group with pain, sensitivity, or complaints 
unrelated to the testicle. From our results we can conclude that physical 
examination alone appears to be sufficient for the first medical consultation in an 
early detection program in cases of men with pain, with sensitivity to palpation, 
and with symptoms unrelated to the testicle. Despite the high specificity of both 
swelling and lump for TC, the sensitivity of these complaints to tumor positivity is 
very low. In the case of a palpable lump and/or a swollen testicle, TUS is 
obligatory to aid the physical examination at the time of the first consultation, 
especially in young men.  
Of the 26 GCTC patients, 13 had S and all had stage I tumors. Among the 13 
NSGCT patients, 4 had clinically detected regional metastases, and 2 had 
hematogenous dissemination. This data suggests that S is detected more frequently 
and earlier in an early detection program than NSGCT. Because of the early stages 
and the high percentage of S tumor markers, had a limited role in an early 
detection program. During the 3-year period, only 3-4% of the estimated TCs in 
Hungary were discovered by the program. The incidence was 0,51% in the entire 
screened population, and 1,66% in the population of patients with complaints and 
findings. This is the same magnitude that was found by other authors. Although 
early detection might help in the identification of some TCs, the efficiency of the 
program is limited. The effect of the program on outcome is uncertain since the 
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contribution of early detection to the probable 100% cure rate cannot be estimated. 
The majority of diagnosed TCs were stage I tumors, and all of the treated patients 
belonged to the good prognostic group: this fact made it possible to apply less 
aggressive treatment and improve the patients’ quality of life.  
In 2004, the US Preventive Services Task Force (USPSTF) concluded that 
screening asymptomatic men for TC was “unlikely to produce any additional 
benefits over clinical detection because of its relative rarity, the lack of evidence 
showing the accuracy of clinical or self-examination, and highly favorable 
outcomes from treatment”. Researchers from the Agency for Healthcare Research 
and Quality in 2010 report that there is “no new evidence to support changing the 
existing guidelines”.The National Cancer Institute (NCI) notes that, on the basis of 
current evidence, "screening for TC would not result in an appreciable decrease in 
mortality, in part because therapy at each stage is so effective." In this context, 
increasing health care education with better public and self awareness could 
improve the figures of early TC. The impact of this educational and early detection 
program in Hungary for TC mortality difficult to be justified. However there were 
a period between 1997 and 2002, where the number of deaths were clearly and 
continuously under the regression curve. In contrary to the NCI statement, our 
educational and screening program that was finished in 1998 may have some 
positive immediate and carry-over effect in the next few years on the figures of 
mortality. This improvement diminishes, ceases in recent years probably due to the 
lack of such programs. 
Population that need to be screened are those men who had cryptorchidism, 
infertility and malformations or abnormalities of the male genital organs in their 
medical history, who had first degree relatives with GCTC. In case of gonadal 
dysgenesia or Klinefelter-syndrome and Down’s-syndrome, patients have to screen 
routinely due to the high incidence of TC. 
Early diagnosis should be based on an educational program for the 
population at risk, the appropriate training of doctors and staff engaged in the 
health care of the young, and –in line with the NCI statement - the use of early 
TUS examination for men with palpable lumps and swollen testicles, especially in 
young men. To detect the disease at an early stage, it is important that young men 
know about the prevalence of TC, can identify the most common early symptoms, 
and are familiar with the performance of TSE
 
It has been pointed out that school 
nurses are in an ideal position to promote awareness of TC and TSE to adolescent 
men. 
6. Thesis 
1. By means of our early detection and screening program, the incidence of 
mortality could be decreased during the time of the program and in the next 
following years. Meanwhile, early diagnosis of TC should be based rather on 
widespread and continuous health education adapting to the curriculum mostly for 
the young population at higher risk, than by means of a screening program. 
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2. The screening of asymptomatic, complaint-free volunteers is not necessary. This 
observation has got into international statements since then. In this group regular 
TSE is recommended. 
3. Further assignation to detailed urological examination by general practitioners 
should be based on evaluating of complaints and clinical findings. The TUS 
examination at short notice for patients who have revealed with swollenness and 
lump, can be recommended. 
4. For certain high-risk groups regular TSE and in case of complaints and/or 
physical findings TUS can be recommended. 
 
Chapter II.: Recent advances in the better decision on diagnosis and 
treatment of inflammatory breast cancer. 
1. Introduction  
Invasive breast cancer (BC) is the most commonly diagnosed malignancy in 
women after skin cancers. 7000-7500 new cases are diagnosed yearly in Hungary, 
and one-fifth to one-fourth of them are expected to die from invasive cancer 
making it the second most frequent cause of cancer deaths in women. Principles of 
diagnosis, treatment and follow-up of primary BC are based on well-accepted 
guidelines (Hungarian, ESMO, NCI, NCCN, St. Gallen Consensus). Locally 
advanced breast cancer (LABC) is defined as stage III disease: Stage IIIA 
(T3N1M0) patients are considered to have resectable LABC, whereas all other 
LABC is considered irresectable.
 
Inflammatory breast cancer (IBC) as the third 
group of LABC defined as T4d disease. 
Primary systemic chemotherapy (PSCT) –or neoadjuvant CT - is 
performed prior to BC surgery. It offers several advantages over standard 
postoperative CT, however, PSCT with classical drug of choice does not offer any 
survival beneﬁts over postoperative CT to date.  
IBC is the most aggressive form of BCs comprising 1-6% (most often 2-3%) 
of all invasive BC cases and had statistically significantly poorer 5-year disease-
free survival than women with either LABC or non-T4 breast cancer. The 
American Joint Committee
 
on Cancer (AJCC) provides the current definition
 
for 
this form of BC, describing it as both a clinical and a pathologic
 
entity  
From a clinical point of view, the first step in treatment of IBC is the 
conversion of the primary irresectable cancer to a resectable one; otherwise this 
the patient is incurable. Getting resectability we must achieve clinical CR (cCR) or 
partial remission (PR); minimal change or stable disease (SD) means abiding in 
the state of irresecability. Beyond other prognostic and predictive factors, response 
to PSCT, particulary achieving pathological complete remission (pCR) dominantly 
determines survival. The multidisciplinary management of IBC includes PSCT and 
radiotherapy (RT). In case of achieving resecablility surgery (ST) must be 
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performed, followed by an appropriate adjuvant treatment. An anthracycline-based 
(A+) regimen in combination with concomitant or sequential taxane is the standard 
PSCT recommended for the treatment of LABC . 
Although the length and components of PSCT in the neoadjuvant setting are 
by and large predefined, there are only few data available specifically for the 
PSCT of IBC. Adding a taxane to an anthracycline-containing regimen further 
improved the DFS in most of the neoadjuvant and adjuvant trials. However there is 
a large degree of heterogenity in evidences regarding the effectiveness of taxane-
containing regimens compared to non-taxane-containing protocols in terms of 
interventions, comparators and populations. It is not quite clear, that in case of 
achieving resecablity with PSCT is it worth to give all cycles before ST or is it 
better to perform a short-term operation and after completing CT with other 
adjuvant modalities. Moreover, if we detect only a minimal change or SD on 
PSCT, then which drugs and in how many cycles should we apply instead and over 
of our PSCT? 
2. Aims of the thesis 
In our thesis we look for the answers of the following questions: 
1. Can we further improve the efficacy (response) of conventional non-
taxane based, A+ protocols with adding a taxene (docetaxel) to an anthracycline 
(epirubicine) in IBC patients? 
2. Can we demonstrate relationship between response to PSCT and survival 
parameters?  
3. Can we demonstrate relationship between number of treatment cycles 
given them pre- and postoperatively and survival parameters? 
4. Which prognostic and predictive factors can predict the probable efficacy 
of PSCT? 
3. Patients and methods 
Clinical records of 82 IBC patients referred to the Multidisciplinary Breast 
Cancer Consulting Committee of the National Institute of Oncology between 
1.1.1997 and 31.12.2004 were analyzed retrospectively. The diagnosis of IBC had 
been set up according to Haagensen’s criteria. In order to evaluate the primary 
tumors and presurgical clinical responses - beyond physical examination - 
mammography and US were performed. State of malignancy was set by aspiration 
cytologies and/or core biopsies as well. Routine staging examinations revaled 
distant metastasis in 8 patient so they were dislosed from further analysis. Four 
IBC patients received docetaxel-carboplatin, and CMF treatments, they were also 
excluded from the further PSCT analysis due to the small number of these cases 
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that could not enter any of the homogenous treatment groups
1
. At least, we could 
analyse the data of 70 patients from the point of PSCT. 
In case of the evaluable 70 patients the following PSCT protocols were used: 
FAC/FEC or AC (, or CEF; these protocols further designated as A+. TE protocol 
consisted docetaxel epirubicine. Postoperative adjuvant chemotherapies were the 
above-mentioned A+ and TE protocols, as well as the TC (docetaxel and 
carboplatin) or CMF (protocols. For the improvement of local control, 
preoperative radiotherapy (RT) could be applied after PSCT by the physician's 
individual pre- or peri-treatment decision. Course of pre- and postoperative RT 
techniques, chemo-, endocrine and anti-HER2-treatments were in accordance with 
accepted institutional practice and clinical guidelines. 
Table 1. Description of patient population 
Patients:  
Age at time of diagnosis (average ± S.D. [range]) 57,38 ± 11,4 [27,5 – 77,0] year 
Menopausal status: 
premenopausal 
perimenopausal 
postmenopausal 
 
25,71% 
2,86% 
71,43% 
Median time to first perception of breast mass to 
diagnosis 
6.0 months 
Median time from diagnosis to start PSCT 22,3 days 
Measurable tumor sizes (average ± S.D.) 
mammography 
ultrasound 
physical examination 
 
40.2 ± 33.6 mm 
30.8 ± 24.7 mm 
56.53 ± 32.1 mm 
 
To determine the efficacy of PSCT, we analyzed the clinical therapeutic 
responses, histological result of surgery, and different survival parameters. The 
evaluation of clinical response was based on the consultant physician’s and the 
surgeon's description given before surgery considering the physical findings and 
preoperative imaging results. Clinical response evaluation with imaging methods 
was usually performed after the 4th - 6th cycles of PSCT. Complete clinical 
remission (cCR) was recorded if any signs or symptoms of IBC have disappeared 
by both physical examination and imaging. Definition of other response 
parameterswere identical to RECIST-criteria. In cases showing irresolvable 
discrepancies between results of physical evaluation and the imaging results, we 
accepted the worse clinical result category. Complete pathological response (pCR) 
was stated if both the invasive and non-invasive parts of the tumor have been 
completely disappeared from the breast and the lymph nodes.  
Progression-free survival (PFS) and overall survival (OS) was defined as 
time from starting PSCT until progression or death from any cause. Censoring 
                                                             
1 Data of these 4 patients were only considered in PSCT + adjuvant CT in the combined analysis. 
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time for living patients was 01.09.2008. or the last contact closest to this date. 
Time to locoregional progression, named LPFS, was defined as time from starting 
chemotherapy to first local recurrence of breast cancer in the mentioned areas. 
Statistical analyses were conducted with using Statistica® 7.1 software 
(StatSoft® Inc., Tulsa, OK, USA). Descriptive stastistics,matched pair univariate 
analysis (Pearson’s χ2-test were performed on qualitative data. For quantitative 
data we used Wilcoxon’s rank sum test and Kruskal-Wallis test. Non-parametric 
comparisons between two groups were made with Mann-Whitney U-test and log-
rank test. Three-year PFS, LPFS, and OS were calculated from the first day of the 
primary chemotherapy and were estimated by using the Kaplan-Meier method. p 
of 0,05 or lower was considered statistically significant. 
4. Results 
1. Comparing the anthracycline-containing, but docetaxel non-containing PSCT 
with the docetaxel-epirubicine PSCT protocol in terms of response. 
The objective RR was 56.8% with the clinical benefit (at least SD) of 92.9%. 
Clinical complete remission (cCR) was shown in 17 patients (24.3%). Results of 
histological evaluations of cCR and pCR patients are provided on Table 2. 
Detailed results comparing the two types of PSCT can be seen on Table. 3.  
Table 2. Results in patients achieved cCR (N=17) 
Not operated 3 
Pathological CR 4   [+1]* (7,14% ) 
Partial response 9  
Stable disease 1  
Histology unavailable (but presence of tumor confirmed) 2 
Histology available: 
DCIS 
Invasive ductal carcinoma 
Invasive mucinosus carcinoma 
Inflammatory breast cancer 
pCR, but lymph node metastasis 
2 
3# 
1 
1 
1 
* one patient with clinically SD became pCR; # one only microscopic in size 
 
Table 3. Clinical and pathological responses according to the PSCTs 
 Clinical Response Pathological Response 
 A+ /% TE/% χ2 p A+/% TE/% χ2 p 
cCR / pCR 13 /27.1 1 /4,5 4.79 0.03 5 /10.4 0 /0 2.47 0.12 
Major response 
(CR+PR) 
26 /54.2 12 /54,5 1.16 0.28 23 /47.9 9 /40.9 0.15 0.70 
Clinical benefit 
(CR+PR+SD) 
44 /91.7 21 /95,5 0.33 0.57 44 /91.7 21 /95.9 0.33 0.59 
All 
 
48 /100 22 /100   48 /100 22 /100   
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Clinical CR rate of patients receiving A+ was significantly better (5 pCRs 
were seen on the non-taxane arm vs nil on the TE arm), however the objective RR 
and the clinical benefit were not different. 
2. Relationship between response to PSCT and survival parameters 
After an average of 2.6±2.4 [0.16-10.0] years of follow-up 50% (n=35) of the 
patients was alive, and 32.9% (n=23) of the entire population was free of disease. 
For the entire population the median PFS was 1.9 year, the median LPFS was 5.4 
years, and the median OS was 4.0 years. 
Patients achieved cCR had a tendency for longer survival parameters 
comparing to PR-SD patients, with a median PFS of 3.7 vs. 1.9 years (p=0.41); 
with a not reached median LPFS vs. 5.0 years (p=0.44) and with an OS of 5.5 vs. 
5.0 years (p=0.79).  
In terms of PFS and OS but not in LPFS, a clear survival advantage was 
demonstrated for patients who achieved pCR. We could not demonstrate any 
difference between the two types of PSCT in terms of survivals. Although the 3-
year PFS/LPFS rates were somewhat higher with the conventional A+ protocols, 
this was not significant and the reverse effect was detected on the OS.  
At the censoring time, proportion of patients dead or alive (A:17/31 vs. TE: 
5/17; χ2=1.13; p=0,29), and without BC or relapsed (A:15/33 vs. TE: 8/14; 
χ2=0.18; p=0.67) was not different. There was no type of comparisons which 
demonstrated any significant difference between the two types of PSCT. Similarly, 
median overall survival and 3 year survival rates were identical in both arms. 
Table 4. Survivals as a function of type of PSCT 
 Median survival 3 y survival 
Type of chemotherapy N PFS 
y 
LPFS 
y 
OS 
y 
 PFS% LPFS 
% 
OS% 
Anthracycline-(non-
taxane) combination 
48 2,28 5,53 4,07  47,1 65,5 60.9 
Docetaxel+epirubicine 22 1,99 not yet 
achiev
ed 
3,86  36,4 57,5 74,8 
Log-rank  
 p 
 0,13 
0,90 
-0,53 
0,60 
-0.39 
0,7 
HR 
(C.I.± 
95%) 
1,30 
(0,18-
2,42) 
1,06 
(0,08-
2,04) 
0,76 
(0,34-
1,19) 
 
Survival parameters were inferior in greater tumors, lymph node positivity, 
higher grade, hormone receptor negativity, HER2 positivity, absence of necrosis in 
tumor, progesterone receptor negativity. In case of pCR, the fact of ST and RT, 
survival parameters were better in univariate analysis. No meaningful multivariate 
analysis can be performed due to the small number of cases. 
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3. Relationship between response to PSCT and adjuvant CT and survival 
parameters 
Fourty-one patients recieved postoperative andjuvant CT and 33 did not
2
. Three 
patients were excluded from the analysis: 2 recieved TC pre- and postoperatively, 
and 1 recieved CMF as PSCT, but nil postoperatively. Two groups were formed: 
in the first group pateints recieved only A+ protocols (N=43; 60,56%); in the 
second they recieved both anthracycline and taxane (docetaxel) (N=28; 39,44%). 
However, in the further statistics, we did not take account whether these protocols 
were given as PSCT and/or adjuvant CT, because we assumed that the fact – 
namely, taxane (docetaxel) was given or not – is more important then the question: 
when it was given. Number of cycles given were identical: A+: 5.9; A+ and 
docetaxel: 5.1; t=1.73 p=0.09). 
Table 5. Survivals as a function of type of PSCT and adjuvant CT:  
 Median survival 3 y survival 
Type of chemotherapy 
N 
PFS 
y 
LPFS 
y 
OS 
y 
 
PFS 
% 
LPFS 
% 
OS 
% 
Anthracycline-(non-
taxane) combination 
43 1.94 5.52 4.07  46.5 61 59.8 
Anthracycline and 
taxane (docetaxel) 
combination 
28 1.99 
Not 
reached 
yet 
4.87  36.6 56 75.3 
Log-rank  
 p  
-0.13 
0.90 
0.38 
0.70 
0.45 
0.65 
HR 
(C.I.± 
95%) 
1.22 
0.43-
1.77 
1.28 
-0.14 -
1.84 
0.59 
0.35-
0.75 
 
At the censoring time, proportion of patients dead or alive (A+:27/16 vs. TE: 
22/6; χ2=1,77; p=0,16), and without BC or relapsed (A+:13/30 vs. TE: 10/18; 
χ2=0,23; p=0,63) was not different. There was no comparisons which 
demonstrated any significant difference between the two types of PSCT. Similarly, 
median overall survival and 3 year survival rates were identical in both arms. 
4. Effect of PSCT or PSCT and adjuvant treatment cycles given on survival 
parameters 
Most patient were treated with 6 cycles of PSCT (n=48, 68.6 %,), 10.0% 
(n=7) got 3 cycles, 17.1% (n=12) received 4-5 cycles, and 4.3% (n=3) had more 
than 6 cycles. In terms of all pre- and postoperative cycles proportion of patients 
received less, than 6 cycles was 7.1% (n=5), 6 cycles: 47.1% (n=33); 7-8 cycles: 
30.0% (n=21); more than 8 cycles: 15.7% (n=15.7). Survival parameters (PFS, 
LPFS, OS) were not significantly different between groups. Those, who were 
treated with less than 6 pre- and postoperative cycles seem to have practically the 
                                                             
2 In this analysis we could enter those 4 patients, who were excluded from the PSCT analysis. 
16 
 
same survival parameters, than those who had 6 cycles or more: PFS: χ2= 5.28, 
p=0.15; LPFS: χ2=1,15, p=0.77; OS: χ2=4.01, p=0.26. 
5. Discussion 
1. Introduction of doxorubicin-based chemotherapy significantly improved 
results in IBC. More intense chemotherapeutical protocols showed a significant 
improvement in both local relapse-free survival and breast cancer specific survival 
compared to AC/MF or FAC. Changing 5FU to taxane (i.e. TEC vs. FEC) in the 
third generation concomitant protocol, showed further significant improvement in 
the neoadjuvant therapy of operable breast cancer. Despite these observations, we 
could not detect significant difference between the A+ and TE protocols, in terms 
of clinical response parameters. An unexpected elevation was seen in pCR rate 
after A+, probably that is due to statistical terms.  
2. The problem of clinical response evaluation is reflected in the observed 
difference in cCR and pCR. Definition of pCR has profound effect on further 
clinical decisions. We found, that cCR was approximately three-fold higher, than 
pCR in our patient population, that may reflect the definition of pCR. Other studies 
demonstrated less (approximately 1,5-2-fold) or the same differences.  
Achieving resecability leading to longer survival is the key point in the 
management of IBC, so the most effective protocols must be chosen.. A positive 
correlation could be seen between response to PSCT in combination with 
multimodal approach and survival: CR patients would have significantly better 
long-term survival than others. The median survival of our patients achieved pCR 
is one year longer than patients reaching only cCR. We could also confirm, that 
achieving pCR renders a greater probability of longer PFS and LPFS, but not 
significant tendency in OS data. Comparing the taxane non-containing protocols to 
concomitant TE protocol in our study, response rates and survival data were 
equivalent. There is no clear explanation for the significant difference observed 
between the two treatment groups in cCR/pCR. One meaningful difference 
detected between the two treatment groups, that could explain the unexpected 
lower response and survival rates on TE arm was the higher PR content in this 
group.  
In a further analysis, we practically could not demonstrate any meaningful 
difference between A+ and docetaxel-containing protocols irrespectively given 
them as PSCTor split them pre- and postoperatively. The practice in which 
therapeutic decisions – i.e. continue or change the inital protocol - based on the 
early response, were evaluated in different trials and the results were 
conflictingDividing the CT into pre- and postoperative parts also seems to be 
equally effective.  This setup has slightly improved the relapse-free survival on 
non IBC population, but it was not demonstrated in IBC series so far. 
Overall, in our selected IBC patient group, we did not detect any meaningful 
differences between A+ and the concomitant TE protocols suggesting, that we 
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should utilize a more intense third generation concomitant or sequential taxane-
antracycline regimens with integrating novel targeted therapies. 
3. Concerning to the question of cycle numbers: results of the studies that 
are in line with this field are non-equivocal. More cycles of CT was an 
independent predictor of pCR in ABCSG-14 trial. Opposing these results in 
GeparTrio trial - in terms of pCR - eight cycles of TAC was not significantly better 
than six cycles, but the majority of these patients has not IBC. – Most of our 
patients got 6 or more cycles of CT, but survival did not improved with ascending 
cycle numbers. Six months length CT (i.e. 6-8 cycles) of CT could be enough for 
patients achieving cCR. However for patients not achieving cCR after 3-4 cycles 
of PSCT, following decision making should make on changing the original PSCT 
to a non-cross-resistant one. This can be given either PSCT or splitting as pre-and 
postoperative treatment. This approach could serve better the patient’s interest, 
than using a fixed 6 cycles of PSCT. 
6. Thesis 
1. Anthracycline-containing, but docetaxel non-containing protocols were equally 
effective with the docetaxel-epirubicine protocol in terms of response. 
2. Patients achieved cCR had a tendency for longer survival parameters comparing 
to PR-SD patients, however we could not demonstrate any difference between 
the two types of PSCT in terms of survivals. 
3. From the point of survival parameters, we could not demonstrate any 
meaningful difference between A+ and taxane-containing protocols 
irrespectively given them as PSCT or split them pre- and postoperatively. 
4. Survival parameters (PFS, LPFS, OS) are not significantly different according 
to the cumulative number of cycles administered pre- and postoperatively. 
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